Toward Wearable EEG-based Alertness Detection System Using SVM with Optimal Minimum Channels

Alertness is the state of attention by high sensory awareness. A lack of alertness is one of the main reasons of serious accidents. Traffic accidents caused by driver’s drowsy driving have a high fatality rate. This paper presents an EEG-based alertness detection system. In order to ensure the convenience and long-term wearing comfort of EEG recordings, the wearable electrode cap will be the principal choice in the future, and the selection of channels will be limited. We first built a 3-D simulated driving platform using Unity3D. Then, we perform an experiment with driving drift task. EEG signals are recorded form frontal and occipital regions. We select data segments using the driving reaction time, classify the state of alertness with a support vector machine (SVM), and select the optimal combination of channels with minimum number of channels. Our results demonstrate that alertness can be classified efficiently with one channel (PO6) at accuracy of 93.52%, with two channels (FP1+PO6) at 95.85% and with three channels (FP1+PO6+PO5 and FP1+PO6+POZ) at 96.11%

Toward Wearable EEG-based Alertness Detection System Using SVM with Optimal Minimum Channels

Alertness is the state of attention by high sensory awareness. A lack of alertness is one of the main reasons of serious accidents. Traffic accidents caused by driver’s drowsy driving have a high fatality rate. This paper presents an EEG-based alertness detection system. In order to ensure the convenience and long-term wearing comfort of EEG recordings, the wearable electrode cap will be the principal choice in the future, and the selection of channels will be limited. We first built a 3-D simulated driving platform using Unity3D. Then, we perform an experiment with driving drift task. EEG signals are recorded form frontal and occipital regions. We select data segments using the driving reaction time, classify the state of alertness with a support vector machine (SVM), and select the optimal combination of channels with minimum number of channels. Our results demonstrate that alertness can be classified efficiently with one channel (PO6) at accuracy of 93.52%, with two channels (FP1+PO6) at 95.85% and with three channels (FP1+PO6+PO5 and FP1+PO6+POZ) at 96.11%

Prognostic Impact of Pregnancy in Korean Patients with Breast Cancer

Background Pregnancy concurrent with, shortly before, or after breast cancer poses unique challenges because hormonal changes in pregnancy potentially interact with breast cancer outcomes. Materials and Methods We studied a cohort of 3,687 female patients of reproductive age (<50 years) with breast cancer, linking a large institutional database and the nationwide claims database to comprehensively capture exposure status and tumor characteristics. Exposures included breast cancer during pregnancy, postpartum breast cancer (<12 months after delivery), and pregnancy after breast cancer. Results Forty-five patients with postpartum breast cancer were significantly more likely to have advanced stage, hormone receptor-negative tumor and to be younger than 35 years at diagnosis than those without postpartum breast cancer. This trend was not observed with 18 patients with breast cancer during pregnancy. The unadjusted 5-year survival rates were 77% versus 96% for patients with postpartum breast cancer versus their counterparts, 89% versus 96% for patients with breast cancer during pregnancy versus their counterparts, and 98% versus 96% for patients with pregnancy after breast cancer versus their counterparts, respectively. In the multivariable analyses, postpartum breast cancer exhibited hazard ratios for death of 1.57 (95% confidence interval [CI], 0.82-2.99), whereas those for breast cancer during pregnancy and pregnancy after breast cancer were 1.09 (95% CI, 0.15-7.91) and 0.86 (95% CI, 0.26-2.83), respectively. Conclusion Postpartum breast cancer, but not breast cancer during pregnancy, was associated with advanced stage, younger age at diagnosis (<35 years), hormone receptor-negative disease, and poorer survival. Pregnancy after breast cancer did not compromise overall survival. Implications for Practice Although pregnancy around the time of diagnosis of breast cancer is expected to become increasingly common with maternal age at first childbirth on the rise, data on the prognostic impact of pregnancy have been inconsistent and rare from Asian populations. In this investigation of a Korean patient cohort with breast cancer, pregnancy-associated breast cancer was associated with advanced stage, younger age at diagnosis (<35 years), hormone receptor-negative disease, and poorer survival. This adverse impact of pregnancy on the prognosis was apparent with postpartum breast cancer but not observed with breast cancer during pregnancy. Pregnancy after breast cancer did not compromise overall survival

Association of insulin, metformin, and statin with mortality in breast cancer patients

Purpose This study investigated the association of insulin, metformin, and statin use with survival and whether the association was modified by the hormone receptor status of the tumor in patients with breast cancer. Materials and Methods We studied 7,452 patients who had undergone surgery for breast cancer at Seoul National University Hospital from 2008 to 2015 using the nationwide claims database. Exposure was defined as a recorded prescription of each drug within 12 months before the diagnosis of breast cancer. Results Patients with prior insulin or statin use were more likely to be older than 50 years at diagnosis and had a higher comorbidity index than those without it (p < 0.01 for both). The hazard ratio (HR) for death with insulin use was 5.7 (p < 0.01), and the effect was attenuated with both insulin and metformin exposure with an HR of 1.2 (p=0.60). In the subgroup analyses, a heightened risk of death with insulin was further prominent with an HR of 17.9 (p < 0.01) and was offset by co-administration of metformin with an HR of 1.3 (p=0.67) in patients with estrogen receptor (ER)-negative breast cancer. Statin use was associated with increased overall mortality only in patients with ER-positive breast cancer with HR for death of 1.5 (p=0.05). Conclusion Insulin or statin use before the diagnosis of breast cancer was associated with an increase in all-cause mortality. Subsequent analyses suggested that metformin or statin use may have been protective in patients with ER-negative disease, which warrants further studies